Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

People assigned female at birth can't get prostate cancer because they don't have a prostate gland. However, women can get a rare type of cancer that develops in the Skene's glands, a pair of organs ...

DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

Eating a diet rich in vegetables and probiotics such as broccoli, turmeric and ginger could help slow the growth of low-risk ...